NSB 12.8% 3.4¢ neuroscientific biopharmaceuticals ltd

Ann: NSB files new patent, page-11

  1. 431 Posts.
    lightbulb Created with Sketch. 119
    it’s been a very clunky process thus far, and I’m concerned that they haven’t been able to recruit a new CEO as of yet.
    I think Paul in the drivers seat is a good thing, as long as he doesn’t have too much on his plate after also being appointed as MD of paradigm, again.

    An update on the early phase trial would also be nice.
 
watchlist Created with Sketch. Add NSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.